Bristol-Myers Squibb Company (BMS) announced Tuesday that it had signed an agreement to acquire biopharmaceutical company ZymoGenetics for approximately $885 million, or $9.75 per share in cash.
The Universal Vaccines of Inovio Biomedical
Inovio is developing a universal flu vaccine engineered to prevent several strains of influenza at once.
